INTRODUCING PROLON, THE REVOLUTIONARY FIVE DAY FASTING MIMICKING PROGRAM

Clinically proven first-to-market meal plan promotes healthy aging, weight loss and cell regeneration

NEW YORK, NY, SEPTEMBER 21, 2016 — Industry leading nutritechnology company L-Nutra today released ProLon, a groundbreaking 5-Day meal program that nourishes the body while promoting cell rejuvenating changes triggered by their scientifically proven plant based meal system.

Developed at the University of Southern California (USC) Longevity Institute, in sponsorship by the National Institute for Aging and the National Institute of Health, ProLon harnesses the latest in life extension research in this game changing Fasting Mimicking Diet (FMD) program.

Water only fasting can be challenging but it induces significant anti-aging changes, rejuvenation and accelerated body healing. ProLon’s 5-day-per month meal program is the first to nourish the body while placing it in fasting mode. It is scientifically proven and clinically tested to induce all the benefits of fasting including cell regeneration, healthy aging and fat driven weight loss.

“ProLon is the first impactful yet practical and natural intervention that enhances the healthy part of our life by optimizing the way we age,” says Dr. Valter Longo, chairman and founder of L-Nutra and the director of the Longevity Institute. “Fasting done periodically is a very powerful and natural way to help the body first recover from the incremental damages inflicted by unhealthy lifestyle and then to rejuvenate its cells and systems. Based on over a decade of research and development, ProLon is scientifically proven to enable people to live longer, healthier lives.”

In the latest clinical trial conducted at USC’s Longevity Institute, 3 cycles of ProLon (5 days per month over a 3-month period) showed statistically significant (p<0.05) improvements on various health metrics: decrease in body fat; decrease in body weight; preservation of lean body mass; preservation of bone density; reduction in fasting glucose and insulin resistance; optimization of cholesterol and triglyceride levels; decrease in IGF-1 (aging marker); decrease in C-reactive protein; elevated mesenchymal/progenitor cells (rejuvenation marker).

The diet is comprised of low-protein, low-carbohydrate, and high good fat ingredients to help the body protect and repair itself naturally, bringing long-term health benefits. The “fasting with food” program features meals ranging from 770 to 1,100 calories per day, packaged in convenient grab-and-go boxes that include energy bars, soups, a variety of snacks, drinks, and supplements. ProLon’s plant-based ingredients consist of fresh olives, vegetables, nuts, seeds, dark chocolate, and herbal teas.

“ProLon represents a major innovation in nutritechnology,” says Joseph Antoun, CEO of L-Nutra. “This is the first time in history that we have a food that someone consumes for 5 days while the body does not recognize it is eating and therefore enters into a protective and regenerative mode to improve overall health, aging and wellbeing.” Dr. Antoun reported that “many consumers like the fact that ProLon is to be consumed over 5 days only per one or two or three months and is not every day’s diet that imposes change to their lifestyle. Consumers reported as well higher energy levels, healthier skin, improved control of food consumption. For these reasons, overall satisfaction consumers from all across the nation is at 90% rate.”

About L-Nutra

L-Nutra is a leading nutri-technology company based in Los Angeles, California. It exclusively licenses from USC Fasting Mimicking Diet (FMD) technologies and develops, markets, and sells them for various indications aimed at increasing healthspan, the healthy part of life. Unlike biological and pharmaceutical drugs, L-Nutra’s natural, plant-based, and effective nutri-technologies mimic and enhance a systemic protectionist and healing effect induced by several consecutive days of fasting. L-Nutra launched on September 21, 2016 the first FMD called ProLon for aging and metabolic health. It is in a phase 2-equivalent trial for chemotherapy-induced side effects and in pre-clinical trials for other chronic diseases such as diabetes, Alzheimer’s, and cardiovascular and autoimmune diseases.

Media Contact:
Danielle Caldwell
Crier Communications
310-274-1072 x214

danielle@crierpr.com